Overview of Medications to Treat Addiction in Primary Care
Upcoming SlideShare
Loading in...5
×
 

Overview of Medications to Treat Addiction in Primary Care

on

  • 766 views

These materials provide information on prescribing details for FDA-approved medications used to treat addiction in primary care. Visit CASAColumbia.org for more details

These materials provide information on prescribing details for FDA-approved medications used to treat addiction in primary care. Visit CASAColumbia.org for more details

Statistics

Views

Total Views
766
Slideshare-icon Views on SlideShare
363
Embed Views
403

Actions

Likes
0
Downloads
13
Comments
0

1 Embed 403

http://www.casacolumbia.org 403

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Overview of Medications to Treat Addiction in Primary Care Overview of Medications to Treat Addiction in Primary Care Presentation Transcript

    • OVERVIEW OF MEDICATIONS TO TREAT ADDICTION IN PRIMARY CARE Prepared by CASAColumbia® February 2014
    • Outline • Introduction • Addiction Involving: − Tobacco/Nicotine − Alcohol − Opioids − Other Drugs • Further Considerations © CASAColumbia 2014 2
    • INTRODUCTION © CASAColumbia 2014 3
    • Addiction For background information on addiction Addiction Medicine: Closing the Gap between Science and Practice1 © CASAColumbia 2014 4
    • Addiction For information on screening, diagnosis, treatment planning & management Overview of Addiction Medicine for Primary Care2 (62 Slides) Overview of Addiction Medicine for Primary Care: Supplement3 (30 Pages) © CASAColumbia 2014 5
    • Stabilization • Withdrawal in some cases can be lifethreatening • Medical management for stabilization/detoxification may be required • Details for these topics can be found on Pages 88-92 of the CASAColumbia® report Addiction Medicine: Closing the Gap between Science and Practice1 © CASAColumbia 2014 6
    • Addiction Treatment • Treat addiction as a primary disease • Address tobacco/nicotine, alcohol & other drugs • Manage co-occurring disorders dopamine transporters © CASAColumbia 2014 7
    • Combined Treatment • Medications & psychosocial therapies • Can increase retention in treatment • Can decrease relapse rates © CASAColumbia 2014 8
    • Combined Treatment • To achieve the best results medications should be combined with psychosocial therapies • Research studies illustrate the effectiveness of various combinations of treatment4-6 • Details for psychosocial therapies can be found on Pages 102-106 of the CASAColumbia® report Addiction Medicine: Closing the Gap between Science and Practice1 © CASAColumbia 2014 9
    • Specialist Referral Consider for Complex Cases • Addiction medicine physicians find a doctor near you • Addiction psychiatrists find a doctor near you Addiction medicine physician: http://www.abam.net/find-a-doctor Addiction psychiatrist: https://application.abpn.com/verifycert/verifyCert.asp?a=4 © CASAColumbia 2014 10
    • ADDICTION INVOLVING TOBACCO/NICOTINE © CASAColumbia 2014 11
    • FDA-Approved Meds Tobacco/Nicotine • varenicline (Chantix) • bupropion (Zyban, Wellbutrin) • nicotine replacement therapy (e.g., patch, gum, lozenge, inhaler, nasal spray) • combinations • combine with psychosocial therapies © CASAColumbia 2014 12
    • varenicline (Chantix) • 3X higher odds of smoking cessation7 • Nicotinic acetylcholine receptor partial agonist8 • Superior to bupropion & single-form nicotine replacement therapy9 © CASAColumbia 2014 13
    • varenicline (Chantix) • Begin 1wk prior to target quit date • Starting dose 0.5mg QD x 3dy • Up to 1mg BID x 12wk extension of 12wk © CASAColumbia 2014 14
    • varenicline (Chantix) • Black Box Warning: neuropsychiatric events • Common Side Effects: headache, insomnia, nausea, abnormal dreams • FDA Warning: increased risk of CV events in patients with known CVD • Meta-analyses show no increased risk of neuropsychiatric events9 or cardiac events9-10 © CASAColumbia 2014 15
    • bupropion (Zyban, Wellbutrin) • 2X higher odds of smoking cessation11 • Inhibits norepinephrine & dopamine uptake12 © CASAColumbia 2014 16
    • bupropion (Zyban, Wellbutrin) • Begin 1wk prior to target quit date • Starting dose 150mg QD x 3dy • Up to 150mg BID x 7-12wk extension of 12wk © CASAColumbia 2014 17
    • bupropion (Zyban, Wellbutrin) • Black Box Warning: neuropsychiatric events • Contraindications: seizure disorder / predisposition; abrupt cessation of alcohol / sedatives; risky use / addiction involving alcohol • Common Side Effects: insomnia, tachycardia, weight loss, headache, lower seizure threshold • Meta-analysis shows no increased risk of neuropsychiatric events9 © CASAColumbia 2014 18
    • nicotine replacement (Nicoderm, Nicorette, Commit, Nicotrol) • 1.5X to 2X higher odds of smoking cessation13 • Nicotine without exposure to other toxins © CASAColumbia 2014 19
    • nicotine replacement (Nicoderm, Nicorette, Commit, Nicotrol) • Contraindications: severe angina, postmyocardial infarction, pregnancy, hypersensitivity • Side Effects: minimal except nasal spray (local irritation, cough, headache, dyspepsia) • Combination long-acting (e.g., patch) & shortacting (e.g., gum) better than single form13 © CASAColumbia 2014 20
    • nicotine replacement (Nicoderm, Nicorette, Commit, Nicotrol) Dosing for 1 cigarette 1mg of nicotine • Patch (OTC): 7/14/21mg, q12-24hr, 8wk taper • Gum (OTC): 2/4mg, q1-2hr, 3mo taper • Lozenge (OTC): 2/4mg, q1-2hr, 3mo taper • Inhaler (Rx): 6-16 cartridges, q24hr, 3-6mo taper • Nasal Spray (Rx): 1-2 sprays, q1hr, 3-6mo taper © CASAColumbia 2014 21
    • nicotine replacement (Nicoderm, Nicorette, Commit, Nicotrol) Delivery method characteristics • Patch (OTC): only long-acting method • Gum (OTC): “chew & park” technique crucial; should not be used with acidic food or liquids • Inhaler (Rx): beneficial for behavioral rituals • Nasal Spray (Rx): fastest absorption, most side effects © CASAColumbia 2014 22
    • ADDICTION INVOLVING ALCOHOL © CASAColumbia 2014 23
    • FDA-Approved Meds Alcohol • acamprosate (Campral) • disulfiram (Antabuse) • naltrexone (ReVia, Depade, Vivitrol) • combine with psychosocial therapies © CASAColumbia 2014 24
    • acamprosate (Campral) • Improves abstinence & treatment retention14 • May modulate glutamate & GABA15 © CASAColumbia 2014 25
    • acamprosate (Campral) • Begin once abstinent for >24hr if possible • Dose at 666mg TID x 6mo • Safe even with severe hepatic disease • Contraindication: severe renal disease • Common Side Effects: diarrhea, fatigue © CASAColumbia 2014 26
    • disulfiram (Antabuse) • Best efficacy with routine use in monitored systems given high rates of noncompliance16 • Aldehyde dehydrogenase inhibitor © CASAColumbia 2014 27
    • disulfiram (Antabuse) • Causes diaphoresis, headache, dyspnea, hypotension, palpitations, nausea, vomiting (when using alcohol) • Monitoring by spouse, supervisor, etc. is highly recommended © CASAColumbia 2014 28
    • disulfiram (Antabuse) • Starting dose: 250-500mg QD x 1-2wk • Maintenance dose: 125-500mg QD x 6mo • Clinicians often start & maintain at 250mg QD • Remains active 14 days after discontinuation • Contraindications: severe myocardial occlusive disease, psychosis, hypersensitivity • Side Effects: hepatitis, psychosis © CASAColumbia 2014 29
    • naltrexone (ReVia, Depade, Vivitrol) • Decreases drinking by 83% over placebo17 • FDA-approved for alcohol or opioids • Mu opioid receptor inhibitor • Genetic factors affect efficacy © CASAColumbia 2014 30
    • naltrexone (ReVia, Depade, Vivitrol) • Only begin after abstinence from opioids >7dy • Starting oral dose 25mg QD (Day 1), 50mg QD (Day 2) • Maintenance oral dose 50mg QD x 6mo • Depot dose 380mg IM q4wk: better compliance • Trial of at least 3mo recommended © CASAColumbia 2014 31
    • naltrexone (ReVia, Depade, Vivitrol) • Black Box Warning: hepatotoxicity • Contraindications: acute hepatitis, liver failure, prescribed opioids • Side Effects: headache, GI distress, syncope, LFT elevation • Literature review suggests no increased risk for causing or worsening hepatic disease18-19 © CASAColumbia 2014 32
    • ADDICTION INVOLVING OPIOIDS © CASAColumbia 2014 33
    • FDA-Approved Meds Opioids • buprenorphine/naloxone (Subutex, Suboxone, Zubsolv) • methadone (Methadose) • naltrexone (ReVia, Depade, Vivitrol)* • combine with psychosocial therapies * details for naltrexone included on previous slides for addiction involving alcohol © CASAColumbia 2014 34
    • buprenorphine/naloxone (Subutex, Suboxone, Zubsolv) • Reduced use & better treatment retention20 • Partial opioid agonist + opioid antagonist • Exercise caution in quantities prescribed per visit due to potential for misuse • Special training required in order to prescribe • See details under section “For Physicians” at buprenorphine.samhsa.gov © CASAColumbia 2014 35
    • buprenorphine/naloxone (Subutex, Suboxone, Zubsolv) • Starting dose 8mg QD (Day 1) 16mg QD (Day 2-3) • Maintenance dose 12-16mg QD • Contraindication: hypersensitivity • Side Effects: respiratory depression, headache, pain, insomnia, GI symptoms © CASAColumbia 2014 36
    • methadone (Methadose) • Reduced use & better treatment retention21 • Long-acting opioid agonist • Distributed only by licensed facilities © CASAColumbia 2014 37
    • methadone (Methadose) • Starting dose 20-40mg QD • Maintenance dose 80-120mg QD • Dose may be less depending on baseline opioid use • Must follow licensed facility protocol, e.g., EKGs © CASAColumbia 2014 38
    • methadone (Methadose) • Contraindications: respiratory depression, severe asthma, ileus, hypersensitivity • Side Effects: QT prolongation, respiratory depression © CASAColumbia 2014 39
    • ADDICTION INVOLVING OTHER DRUGS © CASAColumbia 2014 40
    • FDA-Approved Meds Other Drugs • Currently no FDA-approved medications for addiction involving other drugs • Research & development ongoing for marijuana, cocaine, others • Combine with psychosocial therapies © CASAColumbia 2014 41
    • FURTHER CONSIDERATIONS © CASAColumbia 2014 42
    • For Prescription Drugs Always consider risks of addiction if prescribing • Opioids • Benzodiazepines • Stimulants • Other addictive prescription drugs © CASAColumbia 2014 43
    • For Adolescent Patients • Only buprenorphine/naloxone is FDA-approved for 16 years & older • All other medications are FDA-approved for 18 years & older • Adolescent treatment should focus more on psychosocial therapies © CASAColumbia 2014 44
    • For Elderly Patients • Monitor for drug-drug interactions • For renal insufficiency adjust dosing of varenicline, bupropion, acamprosate, methadone • For hepatic insufficiency adjust dosing of bupropion, buprenorphine/naloxone, methadone, naltrexone (contraindication if severe) © CASAColumbia 2014 45
    • References 1. CASAColumbia. Addiction medicine: closing the gap between science and practice. 2012 Jun. http://www.casacolumbia.org/addiction-research/reports/addiction-medicine 2. CASAColumbia. Addiction medicine: primary care clinical guide. 2013 Aug. http://www.casacolumbia.org/health-careproviders/guide 3. CASAColumbia. Addiction medicine: primary care clinical guide supplement. 2013 Aug. http://www.casacolumbia.org/health-careproviders/guide-supplement 4. Amato L, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD005031. 5. Anton RF, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug;25(4):349-57. 6. Feeney GF, et al. Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust N Z J Psychiatry. 2002 Oct;36(5):622-8. 7. Fiore MC, et al. Clinical practice guideline. Treating tobacco use and dependence: 2008 update. U.S. Department of Health and Human Services, 2008 May. 8. U.S. Food and Drug Administration. Highlights of prescribing information for Chantix (varenicline). 2013 Feb. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021928s030lbl.pdf 9. Cahill K, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013 May 31;5:CD009329. 10. Prochaska JJ, et al. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856. © CASAColumbia 2014 46
    • References 11. Hughes JR, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031. 12. U.S. Food and Drug Administration. Prescribing information: Zyban (bupropion hydrochloride). 2012 Jan. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020711s036lbl.pdf 13. Stead LF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146. 14. Rösner S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD004332. 15. U.S. Food and Drug Administration. Highlights of prescribing information for Campral (acamprosate calcium). 2012 Jan. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021431s015lbl.pdf 16. Laaksonen E, et al. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2008 Jan-Feb;43(1):53-61. 17. Rösner S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD001867. 18. Brewer C, et al. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol. 2004 Mar;9(1):81-7. 19. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Naltrexone: LiverTox Clinical and Research Information on Drug-Induced Liver Injury. http://livertox.nih.gov/Naltrexone.htm 20. Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207. 21. Mattick RP, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD002209. © CASAColumbia 2014 47
    • Acknowledgements • Margot Cohen contributed much of the research and writing for these materials. • The following subject-matter experts served as external reviewers for these materials: Kevin Kunz, M.D., M.P.H., Frances Levin, M.D., Charles O’Brien, M.D., Ph.D. • Funding was provided by The Joseph A. Califano, Jr. Institute for Applied Policy. © CASAColumbia 2014 48
    • Ending Addiction Changes Everything www.casacolumbia.org